Full Breakdown
Danone Navigates Sales Growth Amid Infant Formula Recalls
2/20/2026, 9:05:29 PM
Overview of the Current Situation
Danone, the French food giant known for brands such as Activia yogurt and Evian water, has reported a 4.5% increase in like-for-like sales for the financial year 2025, totaling €27.3 billion. This growth was primarily driven by strong performance in China, North Asia, and Oceania, despite facing challenges from recent infant formula recalls due to contamination concerns. The company anticipates that these recalls could impact sales by up to €70 million ($82.4 million) in the upcoming quarter.
Financial Performance and Growth Drivers
In the fourth quarter of 2025, Danone's like-for-like sales rose by 4.7%, exceeding analyst expectations. The company attributed this growth to its health-focused portfolio, particularly in specialized nutrition and high-protein products. CEO Antoine de Saint-Affrique noted that the recurring operating margin increased to 13.4%, and earnings per share rose by 4.6% to €3.80. The company also reported a cash flow of €2.8 billion, surpassing analyst forecasts.
Impact of Infant Formula Recalls
Danone, along with competitors like Nestlé, has faced significant challenges due to recalls of infant formula products linked to the toxin cereulide. The recalls have affected operations in over 60 countries, with Danone particularly exposed as approximately 17% of its total profits come from infant formula sales in China. CFO Juergen Esser indicated that the recalls would have a one-off impact of 0.5% to 1% on first-quarter sales, which the company does not consider material.
Regional Performance Insights
The performance varied significantly across regions. While the Asia-Pacific region saw exceptional growth, with a 10.4% increase in sales during the fourth quarter, North America lagged behind expectations despite a solid performance in high-protein segments. Saint-Affrique acknowledged the need for improvement in the U.S. market, particularly in creamers and plant-based products.
Future Outlook and Strategic Focus
Looking ahead, Danone maintains a positive outlook for 2026, projecting like-for-like sales growth between 3% and 5%. The company aims to capitalize on health trends, particularly in gut health and protein consumption, as it continues to invest in innovation and capabilities. Saint-Affrique emphasized the importance of a disciplined approach in a volatile market, stating, “We remain committed to our science-based and consumer and patient-centric approach.”
Criticism and Market Reactions
Despite the overall positive financial performance, Danone's stock has faced pressure, declining approximately 5.2% this year amid the recalls. Analysts have expressed concerns about the potential long-term impact on consumer loyalty, particularly regarding infant formula, as parents may turn to alternative brands during this period.
Verbatim Quotes
- “Antoine de Saint-Affrique, CEO of Danone, stated, “In 2025, we again delivered broad-based, quality growth, reaffirming the strength and resilience of our health-focused portfolio.” — Antoine de Saint-Affrique, CEO of Danone
- “The recall of several industry players at the same time has created some disruption on the shelf,” — Juergen Esser, CFO of Danone
- “We need to step up our game” — Antoine de Saint-Affrique, CEO of Danone
Danone's ability to navigate these challenges while continuing to grow its sales will be closely monitored by investors and analysts in the coming quarters.
